Int. J. Mol. Sci. 2013, 14(5), 9536-9555; doi:10.3390/ijms14059536
Review

Targeting Signaling Pathways in Epithelial Ovarian Cancer

1 Institute of Pathology, Medical University Graz, Auenbruggerplatz 25, A-8036 Graz, Austria 2 Department of Internal Medicine, Division of Clinical Oncology, Medical University Graz, A-8036 Graz, Austria 3 Department of Obstetrics and Gynecology, Medical University Graz, A-8036 Graz, Austria 4 Department of Pathology, General Hospital Graz West, Goestinger Straße 22, A-8020 Graz, Austria These authors contributed equally to this work.
* Authors to whom correspondence should be addressed.
Received: 11 March 2013; in revised form: 13 April 2013 / Accepted: 22 April 2013 / Published: 2 May 2013
(This article belongs to the Special Issue Molecular Bases of Cancer Research)
PDF Full-text Download PDF Full-Text [6910 KB, uploaded 2 May 2013 11:10 CEST]
Abstract: Ovarian carcinoma (OC) is the most lethal gynecological malignancy. Response to platinum-based chemotherapy is poor in some patients and, thus, current research is focusing on new therapy options. The various histological types of OC are characterized by distinctive molecular genetic alterations that are relevant for ovarian tumorigenesis. The understanding of these molecular pathways is essential for the development of novel therapeutic strategies. Purpose: We want to give an overview on the molecular genetic changes of the histopathological types of OC and their role as putative therapeutic targets. In Depth Review of Existing Data: In 2012, the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, was approved for OC treatment. Bevacizumab has shown promising results as single agent and in combination with conventional chemotherapy, but its target is not distinctive when analyzed before treatment. At present, mammalian target of rapamycin (mTOR) inhibitors, poly-ADP-ribose polymerase (PARP) inhibitors and components of the EGFR pathway are in the focus of clinical research. Interestingly, some phytochemical substances show good synergistic effects when used in combination with chemotherapy. Conclusion: Ongoing studies of targeted agents in conjunction with chemotherapy will show whether there are alternative options to bevacizumab available for OC patients. Novel targets which can be assessed before therapy to predict efficacy are needed. The assessment of therapeutic targets is continuously improved by molecular pathological analyses on tumor tissue. A careful selection of patients for personalized treatment will help to reduce putative side effects and toxicity.
Keywords: ovarian cancer; molecular carcinogenesis; targeted therapy

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Smolle, E.; Taucher, V.; Pichler, M.; Petru, E.; Lax, S.; Haybaeck, J. Targeting Signaling Pathways in Epithelial Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 9536-9555.

AMA Style

Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J. Targeting Signaling Pathways in Epithelial Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(5):9536-9555.

Chicago/Turabian Style

Smolle, Elisabeth; Taucher, Valentin; Pichler, Martin; Petru, Edgar; Lax, Sigurd; Haybaeck, Johannes. 2013. "Targeting Signaling Pathways in Epithelial Ovarian Cancer." Int. J. Mol. Sci. 14, no. 5: 9536-9555.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert